Clinical Trials Logo

Filter by:
NCT ID: NCT03877237 Not yet recruiting - Clinical trials for Heart Failure With Reduced Ejection Fraction (HFrEF)

DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction

Start date: April 12, 2019
Phase: Phase 3
Study type: Interventional

International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)

NCT ID: NCT03877224 Not yet recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction (HFpEF)

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

Start date: April 5, 2019
Phase: Phase 3
Study type: Interventional

International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction (HFpEF)

NCT ID: NCT03856047 Recruiting - Obesity Clinical Trials

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study. As well as taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight. Participants will either take NNC0174-0833, liraglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to take one injection once a week or once a day, depending on the treatment. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 8 months. Participants will have 12 clinic visits with the study doctor.

NCT ID: NCT03851588 Not yet recruiting - HIV Infections Clinical Trials

Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis

RADIANT-TB
Start date: May 1, 2019
Phase: Phase 2
Study type: Interventional

The investigators propose to conduct a phase 2 randomised (1:1) double-blind placebo-controlled trial of the dolutegravir-lamivudine-tenofovir fixed dose combination tablet daily with an additional 50 mg dose of dolutegravir/matching placebo taken 12 hours later in ART-naïve HIV-infected patients on rifampicin-based anti-tuberculosis therapy. The hypothesis is that virologic outcomes with standard dose dolutegravir-based ART will be acceptable in patients on rifampicin-based anti-tuberculosis therapy.

NCT ID: NCT03851159 Not yet recruiting - Tuberculosis Clinical Trials

Nyaditum Resae® as a Co-adjuvant During First-line Treatment for Active Pulmonary Tuberculosis and Its Impact on the Gut Microbiota

Start date: February 2019
Phase: N/A
Study type: Interventional

This will be the first study to evaluate the use of Nyaditum resae® as a potential agent for reducing antibiotic-associated gut dysbiosis in patients with drug-susceptible TB, and potentially improving clinical and microbiological markers of outcome

NCT ID: NCT03849027 Not yet recruiting - Pain Clinical Trials

MethOxyflUraNe at moderaTe High AltItudes for PAIN Management

MOUNTAIN-PAIN
Start date: May 2019
Phase: Phase 4
Study type: Interventional

A randomised, double-blind, cross-over study to assess the analgesic effect of methoxyflurane at moderate high altitudes in a wilderness field setting. Phase IV, randomised, double-blind, cross-over clinical trial to evaluate the analgesic effect of methoxyflurane at moderate high altitudes in a wilderness field setting, in 24 healthy volunteers

NCT ID: NCT03836625 Not yet recruiting - HIV/AIDS Clinical Trials

CareConekta: A Smartphone App to Improve Engagement in HIV Care

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

Population mobility is common in South Africa, but important research gaps exist describing this mobility and its impact on engagement in HIV care, particularly among pregnant and postpartum women. Through this study, the investigators propose to test a smartphone application - CareConekta - to conduct essential formative work on mobility and evaluate this app as an intervention to facilitate engagement in HIV care during times of mobility. This work is critical to adapting CareConekta for widespread use, providing critical information about mobility during the peripartum period and the impact on engagement in HIV care, and piloting this intervention to improve engagement.

NCT ID: NCT03834571 Not yet recruiting - HIV Infection Clinical Trials

Standard Chemotherapy and Radiation Therapy With or Without Paclitaxel and Carboplatin in Treating HIV-Positive Women With Locally Advanced Cervical Cancer

Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well standard chemotherapy and radiation therapy given with or without paclitaxel and carboplatin work in treating human immunodeficiency virus (HIV)-positive women with cervical cancer that has spread to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as cisplatin, paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy to the pelvis destroys potential cancer cells in the pelvic area and significantly reduces the risk of tumor recurrence in the pelvic area. It is not yet known if giving chemotherapy and radiation therapy with or without paclitaxel and carboplatin, may work better in treating HIV-positive patients with advanced cervical cancer.

NCT ID: NCT03830866 Recruiting - Clinical trials for Locally Advanced Cervical Cancer

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

CALLA
Start date: February 15, 2019
Phase: Phase 3
Study type: Interventional

This is a randomized, multi-center, double-blind, placebo-controlled, global, Phase III study to determine the efficacy and safety of durvalumab + Chemoradiotherapy versus Chemoradiotherapy alone as treatment in Women With Locally Advanced Cervical Cancer

NCT ID: NCT03821025 Recruiting - Biliary Stricture Clinical Trials

Self-expandable Metal Stents Versus Multiple Plastic Stents for Palliation of Biliary Obstruction

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

A randomised clinical trial to compare the clinical efficacy of multiple plastic stents to fully covered self expanding metal stents in the palliation of distal malignant biliary obstruction in patients with irresectable tumours.